Navigation Links


act in Biological Products

Rabbit Anti-Glutamate receptor 1, phospho (Ser845) Polyclonal Antibody, Unconjugated from GeneTex

Description:... Polyclonal Phosphorylated Anti-GluR1 Glutamate is the main excitatory neurotransmitter in the brain. For many years it had been considered to act only on the ligand-gated receptor channels-termed NMDA, AMPA and kainate receptors that are involved in the fast excitatory synaptic transmission. Rec...
Company:GeneTex

Anti-PEBP Polyclonal Antibody, unconjugated, Clone ZLK.17 from Invitrogen

Description:.... Serine proteases degrade components of the extracellular matrix to allow outgrowth of neuronal processes or cell migration, promote cell death, and act as mitogenic or survival factors. The activity of the serine protease is regulated by their inhibitors. PEBP is important in the outgrowth and mainte...
Company:Invitrogen

Mouse Anti-HDAC8 Monoclonal Antibody, Unconjugated, Clone HDAC8-48 from GeneTex

Description:...sponsible for reversible acetylation/deacetylation processes are histone acetyltransferases(HATs) and histone deacetylases (HDACs), respectively. HATs act as transcriptional coactivators, and HDACs are part of transcriptional corepressor complexes. Mammalian HDACs can be divided into three classes accord...
Company:GeneTex

MDR1 Shift Assay from CHEMICON

Description:...onformational changes in MDR1 that occur upon transport of MDR1 substrates. Thus, the kit may be used to determine the extent to which small molecules act as transport substrates for MDR1. Because UIC2 binding is drastically increased in the presence of MDR1 substrates, the MDR1 Shift Assay can be utiliz...
Company:CHEMICON

TransIT-siQUEST Transfection Reagent from Mirus Bio Corporation

Description:...nhibition of target mRNA can be realized without introducing an interferon response. These short dsRNA, referred to as small interfering RNAs (siRNA), act catalytically at sub-molar ratios to cleave greater than 95% of the target mRNA in the cell. The RNA interference effect can be long-lasting and may b...
Company:Mirus Bio Corporation

TransIT-siQUEST Transfection Reagent from Mirus Bio Corporation

Description:...nhibition of target mRNA can be realized without introducing an interferon response. These short dsRNA, referred to as small interfering RNAs (siRNA), act catalytically at sub-molar ratios to cleave greater than 95% of the target mRNA in the cell. The RNA interference effect can be long-lasting and may b...
Company:Mirus Bio Corporation

SlowFade Antifade Kit from Molecular Probes (Invitrogen)

Description:... The active ingredient in Molecular Probes. SlowFadeAntifade Kits is 1,4-diazabicyclo[2.2.2]octane (DABCO), which appears to act as a free radical scavenger that extends useful fluorescence emission. Our original SlowFade formulation (S-2828) was designed to reduce the fading ra...
Company:Molecular Probes (Invitrogen)
Other TagsAddictAddictBTSCJD
Breaking Biology News(10 mins):Rodent smoke screen 2Superior offspring without genetic modification 2Plate-eating good: Université de Montréal professor designs edible tableware 2Labopharms response for novel trazodone formulation accepted by FDA as complete Designated as Class 2 resubmission 55334 1Labopharms response for novel trazodone formulation accepted by FDA as complete Designated as Class 2 resubmission 55334 2Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 1Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 2Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 3Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 4Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 5Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 6Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 7Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 8ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once Daily Xibrom 28TM 29 0 09 25 4897 1ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once Daily Xibrom 28TM 29 0 09 25 4897 2ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once Daily Xibrom 28TM 29 0 09 25 4897 3
Other Contentstubercletubercleacheachetummytuberoustularemia